Key Highlights

• Pre‑funded warrants covering up to 960,000 common shares were sold at a combined price of $3.1249 per unit.

• The transaction generated gross proceeds of approximately $3.0 million, which will be directed to working capital.

• Liquidated damages are set at 1% per month, capped at a total of 6% of the investor’s commitment.

Cadrenal Therapeutics (NASDAQ: CVKD) closed a private placement on July 1 2026 under Nasdaq at‑the‑market rules. The agreement, signed June 30 2026, provided for the issuance of pre‑funded warrants and two series of common warrants.

Deal Structure

The placement involved pre‑funded warrants that allow the purchase of up to 960,000 shares of Cadrenal’s common stock, which carries a $0.001 par value.

Pricing and Proceeds

Each unit of pre‑funded and accompanying common warrants was priced at $3.1249. The combined offering yielded gross proceeds of approximately $3.0 million, which the company intends to allocate to working capital needs.

Warrant Terms

The pre‑funded warrants carry an exercise price of $0.0001 per share and may be exercised at any time without expiration. Series C‑1 warrants become exercisable upon stockholder approval and expire five years after the later of approval or registration. Series C‑2 warrants are exercisable immediately and expire 24 months after the effective date.

Registration Rights

The company signed a registration rights agreement committing to file a resale registration statement within 15 days and to achieve effectiveness within 45 days, extending to 75 days if the SEC conducts a full review. If these deadlines are not met, the agreement stipulates liquidated damages of 1% per month, limited to a cumulative 6% of the invested amount.

Use of Funds

The net proceeds from the private placement are earmarked for working capital, supporting Cadrenal’s ongoing operational and developmental activities.

Governance and Compliance

The purchase agreement includes customary representations, covenants, and indemnification provisions. Cadrenal is prohibited from issuing additional common stock or equivalents for 60 days and from entering variable rate transactions for one year, with limited exceptions for an at‑the‑market facility after the initial 60‑day period.

 

This article is for informational purposes only and does not constitute financial advice. Please consult a licensed financial adviser before making investment decisions.